ADC Therapeutics (ADCT) Hisse Özeti
ADC Therapeutics SA, İsviçre ve Amerika Birleşik Devletleri'nde antikor ilaç konjugatı (ADC) teknoloji platformu sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
ADCT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ADC Therapeutics SA Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.03 |
| 52 Haftanın En Yüksek Seviyesi | US$4.98 |
| 52 Haftanın En Düşük Seviyesi | US$1.02 |
| Beta | 1.77 |
| 1 Aylık Değişim | -73.32% |
| 3 Aylık Değişim | -74.94% |
| 1 Yıllık Değişim | -71.93% |
| 3 Yıllık Değişim | -59.13% |
| 5 Yıllık Değişim | -95.36% |
| Halka arzdan bu yana değişim | -96.53% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 28
ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings Potential
Analysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.Analiz Makalesi • May 07
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report
It's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...Recent updates
Anlatı Güncellemesi • May 28
ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings Potential
Analysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.Analiz Makalesi • May 07
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report
It's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...Seeking Alpha • May 05
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
Summary ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026. ADCT's $231M cash runway extends into 2028, minimizing near-term dilution risk and supporting ongoing clinical development. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 03
ADCT: Updated Capital Plans And Refined Assumptions Will Support Future Upside Potential
Analysts have increased their price target on ADC Therapeutics by $1, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that they believe better align the valuation with current fundamentals and expectations. Analyst Commentary Despite the modest $1 lift in the price target, recent commentary around ADC Therapeutics still carries a cautious tone.Anlatı Güncellemesi • Apr 19
ADCT: Refined Risk And Earnings Assumptions Will Support Future Upside Potential
Analysts raised their price target on ADC Therapeutics by $1, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively fine tune their outlook rather than overhaul it. Analyst Commentary Bearish analysts are treating the latest US$1 price target adjustment as a refinement rather than a signal of strong conviction, and their commentary leans cautious around execution, valuation and growth visibility.Anlatı Güncellemesi • Apr 05
ADCT: Refreshed Revenue And Margin Assumptions Will Strengthen Future Earnings Power
Analysts have lifted their price target on ADC Therapeutics by $1, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary While the latest price target adjustment reflects refreshed modeling on discount rates, revenue assumptions, margins and future P/E, bearish analysts are still flagging several areas of concern that they see as reasons to stay cautious.Anlatı Güncellemesi • Mar 21
ADCT: Higher Revenue Assumptions Will Support Stronger Future Earnings Power
Analysts have lifted their price target fair value for ADC Therapeutics from $5.00 to $6.00, citing updated assumptions for revenue growth, profit margins and future P/E that change their overall assessment of risk and return. Valuation Changes Fair Value: raised from $5.00 to $6.00 per share, indicating a higher assessed intrinsic value.
Anlatı Güncellemesi • Mar 04
ADCT: Higher Revenue Outlook And Richer P/E Multiple Will Support Upside
Analysts have trimmed their price target on ADC Therapeutics to $7.50 from $8.20, citing updated assumptions that combine higher projected revenue growth with lower expected profit margins and a higher future P/E multiple. Valuation Changes Fair Value: reduced from $8.20 to $7.50, a modest cut to the target level used in the model.Analiz Makalesi • Feb 05
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
ADC Therapeutics SA's ( NYSE:ADCT ) price-to-sales (or "P/S") ratio of 6.7x might make it look like a buy right now...Analiz Makalesi • Sep 30
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31%
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 31% in...Analiz Makalesi • May 27
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable
Key Insights ADC Therapeutics to hold its Annual General Meeting on 3rd of June CEO Ameet Mallik's total compensation...Analiz Makalesi • May 17
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results
ADC Therapeutics SA ( NYSE:ADCT ) just released its first-quarter report and things are looking bullish. Results...Analiz Makalesi • Apr 04
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 31% in the last thirty...
Yeni Anlatı • Apr 03
Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options
Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.Seeking Alpha • Mar 25
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Summary ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion. Despite a challenging competitive landscape, ADCT's current valuation and cash position make it a high-risk/high-reward investment, meriting a "Buy" sentiment with caution. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 10
Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$1.47 ADC...Analiz Makalesi • Feb 12
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 26% in the last thirty...Seeking Alpha • Dec 12
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Summary Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034. Antibody-drug conjugate with monoclonal antibody directed CD-22 ADCT-602 is being explored in a phase 1/2 study for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 16
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
ADC Therapeutics SA ( NYSE:ADCT ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Jul 18
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Those holding ADC Therapeutics SA ( NYSE:ADCT ) shares would be relieved that the share price has rebounded 34% in the...Seeking Alpha • Jun 06
Limiting Concerns On ADC Therapeutics' Prospects
Summary ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors. Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues. ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia. ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway. Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating. Read the full article on Seeking AlphaAnaliz Makalesi • May 30
ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
The ADC Therapeutics SA ( NYSE:ADCT ) share price has fared very poorly over the last month, falling by a substantial...Analiz Makalesi • May 10
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
ADC Therapeutics SA ( NYSE:ADCT ) shareholders are probably feeling a little disappointed, since its shares fell 3.4...Seeking Alpha • Mar 19
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
ADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Analiz Makalesi • Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 38% in...Seeking Alpha • Dec 29
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Summary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$2.71 Current share...Seeking Alpha • Dec 01
ADC Therapeutics: Navigating A Swirling Drain
Summary ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024. Read the full article on Seeking AlphaSeeking Alpha • Aug 29
ADC Therapeutics: Slowly Moving Toward Solvency
Summary ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship product. They are trading below their enterprise value, making them a potentially strong opportunity for risk-tolerant investors. Read the full article on Seeking AlphaHissedar Getirileri
| ADCT | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -69.7% | -1.4% | -0.1% |
| 1Y | -71.9% | 30.9% | 26.3% |
Getiri vs. Endüstri: ADCT geçen yıl % 30.9 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: ADCT geçen yıl % 26.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ADCT volatility | |
|---|---|
| ADCT Average Weekly Movement | 18.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: ADCT hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: ADCT 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 13% dan 19% a yükseldi.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2011 | 191 | Ameet Mallik | www.adctherapeutics.com |
ADC Therapeutics SA, İsviçre ve Amerika Birleşik Devletleri'nde antikor ilaç konjugatı (ADC) teknoloji platformu sunmaktadır. Şirketin amiral gemisi ürünü CD19'a yönelik bir ADC olan ZYNLONTA, ABD Gıda ve İlaç İdaresi'nden hızlandırılmış onay, Avrupa Komisyonu'ndan şartlı onay ve Çin Ulusal Tıbbi Ürünler İdaresi'nden iki veya daha fazla sistemik tedaviden sonra nükseden veya refrakter diffüz büyük B hücreli lenfoma (DLBCL) tedavisi için şartlı onay almıştır. Şirket ayrıca ZYNLONTA'yı uluslararası pazarlara ve foliküler lenfoma (FL) ve marjinal bölge lenfoması (MZL) dahil olmak üzere DLBCL ve indolent lenfomaların önceki basamaklarına tek ajan olarak ve LOTIS-5 doğrulayıcı Faz 3 klinik çalışması ve LOTIS-7 Faz 1b klinik çalışmasının yanı sıra araştırmacı tarafından başlatılan çalışmalar (IIT'ler) yoluyla kombinasyon halinde genişletmeye devam etmeyi amaçlamaktadır.
ADC Therapeutics SA Temel Bilgiler Özeti
| ADCT temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$167.89m |
| Kazançlar(TTM) | -US$136.99m |
| Gelir(TTM) | US$79.18m |
1.7x
P/S Oranı-1.0x
F/K OranıADCT aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ADCT gelir tablosu (TTM) | |
|---|---|
| Gelir | US$79.18m |
| Gelir Maliyeti | US$100.02m |
| Brüt Kâr | -US$20.85m |
| Diğer Giderler | US$116.14m |
| Kazançlar | -US$136.99m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.08 |
| Brüt Marj | -26.33% |
| Net Kâr Marjı | -173.02% |
| Borç/Özkaynak Oranı | -201.2% |
ADCT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/05 03:04 |
| Gün Sonu Hisse Fiyatı | 2026/06/05 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ADC Therapeutics SA 21 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Naureen Quibria | Capital One Securities, Inc. |